The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,496,686 in first-year total cost, median $499,999.
Most frequent study sections
- Special Emphasis Panel[ZRG1 EMS-H (55)]2
- Drug Discovery and Molecular Pharmacology B Study Section[DMPB]1
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL1
- UNIVERSITY OF CALIFORNIA, SAN DIEGO1
- VANDERBILT UNIVERSITY MEDICAL CENTER1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Ubiquitin D as a potential therapeutic target for NASH, HCC and chronic kidney diseases1R01DK133930-01A1 | DHAR, DEBANJAN | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $500,000 | ZRG1 |
| 2023 | Them1 Inhibitors for the Management of Non-Alcoholic Fatty Liver Disease1R01DK133988-01A1 | COHEN, DAVID E. | BRIGHAM AND WOMEN'S HOSPITAL, MA | $499,999 | ZRG1 |
| 2023 | Preclinical validation of Kir4.1/5.1 inhibitors for overcoming diuretic resistance1R01DK137302-01 | DENTON, JEROD S. | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $496,687 | DMPB |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.